Physician profile
Fred J Balis
NPI 1861447625
$545.41
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $233 · 2021: $70.15 · 2022: $32.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $192.90 | 2019-2022 | |
| Pfizer INC. | $98.06 | 2019-2022 | |
| Allergan, INC. | $40.97 | 2019 | |
| Abbvie INC. | $33.80 | 2019-2021 | |
| Emd Serono, INC. | $32.55 | 2020-2021 | |
| Amgen INC. | $32.07 | 2019 | |
| Astellas Pharma US INC | $20.99 | 2020 | |
| Gilead Sciences, INC. | $20.43 | 2020 | |
| Sanofi Pasteur INC. | $17.66 | 2020 | |
| Merck Sharp & Dohme LLC | $14.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.51 | 2020 | |
| Opko Pharmaceuticals, LLC | $14.41 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $12.23 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Balis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.